(SYK) Stryker - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8636671013
Joint Implants, Surgical Instruments, Spinal Hardware, Stroke Devices, Orthobiologics
Dividends
| Dividend Yield | 0.92% |
| Yield on Cost 5y | 1.48% |
| Yield CAGR 5y | 8.30% |
| Payout Consistency | 93.4% |
| Payout Ratio | 28.0% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 21.2% |
| Value at Risk 5%th | 33.5% |
| Relative Tail Risk | -3.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -16.52 |
| CAGR/Max DD | 1.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.433 |
| Beta | 0.696 |
| Beta Downside | 0.740 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.56% |
| Mean DD | 4.74% |
| Median DD | 4.41% |
Description: SYK Stryker December 02, 2025
Stryker Corporation (NYSE: SYK) is a U.S.-based medical-technology firm that sells a broad portfolio of surgical, neuro-technology, and orthopaedic products in roughly 75 countries. Its business is split between the MedSurg & Neurotechnology segment-which includes surgical navigation, AI-enabled virtual-care platforms, stroke-treatment devices, cranial and maxillofacial tools, and orthobiologic solutions-and the Orthopaedics segment, which focuses on total joint replacement implants (hip, knee, shoulder), trauma/extremity fixation, and thoracolumbar spinal systems.
Key recent metrics: FY 2024 revenue reached $19.4 billion, up 6 % YoY, with an operating margin of 18 % driven by strong demand for minimally invasive spine and joint-replacement products. R&D spending remained at $1.6 billion (≈8 % of sales), reflecting a strategic push into AI-assisted surgical navigation and next-generation biologics. The orthopaedic market is buoyed by demographic trends-U.S. adults 65+ are projected to grow from 56 million in 2023 to 78 million by 2035-supporting long-term volume growth, while Medicare reimbursement reforms and supply-chain volatility are the primary macro-level risks.
For a deeper dive into how these drivers translate into valuation insights, you might explore the detailed analyst models on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (2.94b TTM) > 0 and > 6% of Revenue (6% = 1.46b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.83% (prev 31.87%; Δ -6.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 4.83b > Net Income 2.94b (YES >=105%, WARN >=100%) |
| Net Debt (13.34b) to EBITDA (4.66b) ratio: 2.86 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (386.7m) change vs 12m ago 0.29% (target <= -2.0% for YES) |
| Gross Margin 62.63% (prev 61.28%; Δ 1.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.65% (prev 50.13%; Δ 3.52pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 21.99 (EBITDA TTM 4.66b / Interest Expense TTM 159.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.58
| (A) 0.13 = (Total Current Assets 13.71b - Total Current Liabilities 7.41b) / Total Assets 47.06b |
| (B) 0.42 = Retained Earnings (Balance) 19.96b / Total Assets 47.06b |
| (C) 0.08 = EBIT TTM 3.50b / Avg Total Assets 45.45b |
| (D) 0.76 = Book Value of Equity 19.23b / Total Liabilities 25.27b |
| Total Rating: 3.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.63
| 1. Piotroski 8.50pt |
| 2. FCF Yield 2.62% |
| 3. FCF Margin 16.71% |
| 4. Debt/Equity 0.76 |
| 5. Debt/Ebitda 2.86 |
| 6. ROIC - WACC (= 0.11)% |
| 7. RoE 13.92% |
| 8. Rev. Trend 90.00% |
| 9. EPS Trend 38.79% |
What is the price of SYK shares?
As of December 03, 2025, the stock is trading at USD 366.68 with a total of 1,561,122 shares traded.
Over the past week, the price has changed by -2.24%, over one month by +2.38%, over three months by -5.75% and over the past year by -5.04%.
Over the past week, the price has changed by -2.24%, over one month by +2.38%, over three months by -5.75% and over the past year by -5.04%.
Is SYK a buy, sell or hold?
Stryker has received a consensus analysts rating of 4.06.
Therefore, it is recommended to buy SYK.
- Strong Buy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SYK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 429 | 17% |
| Analysts Target Price | 429 | 17% |
| ValueRay Target Price | 395.6 | 7.9% |
SYK Fundamental Data Overview November 29, 2025
Market Cap USD = 142.37b (142.37b USD * 1.0 USD.USD)
P/E Trailing = 49.0501
P/E Forward = 24.8756
P/S = 5.8395
P/B = 6.5353
P/EG = 1.8997
Beta = 0.899
Revenue TTM = 24.38b USD
EBIT TTM = 3.50b USD
EBITDA TTM = 4.66b USD
Long Term Debt = 14.85b USD (from longTermDebt, last quarter)
Short Term Debt = 1.75b USD (from shortTermDebt, last quarter)
Debt = 16.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.34b USD (from netDebt column, last quarter)
Enterprise Value = 155.62b USD (142.37b + Debt 16.59b - CCE 3.34b)
Interest Coverage Ratio = 21.99 (Ebit TTM 3.50b / Interest Expense TTM 159.0m)
FCF Yield = 2.62% (FCF TTM 4.07b / Enterprise Value 155.62b)
FCF Margin = 16.71% (FCF TTM 4.07b / Revenue TTM 24.38b)
Net Margin = 12.07% (Net Income TTM 2.94b / Revenue TTM 24.38b)
Gross Margin = 62.63% ((Revenue TTM 24.38b - Cost of Revenue TTM 9.11b) / Revenue TTM)
Gross Margin QoQ = 63.60% (prev 62.27%)
Tobins Q-Ratio = 3.31 (Enterprise Value 155.62b / Total Assets 47.06b)
Interest Expense / Debt = 0.96% (Interest Expense 159.0m / Debt 16.59b)
Taxrate = 16.52% (170.0m / 1.03b)
NOPAT = 2.92b (EBIT 3.50b * (1 - 16.52%))
Current Ratio = 1.85 (Total Current Assets 13.71b / Total Current Liabilities 7.41b)
Debt / Equity = 0.76 (Debt 16.59b / totalStockholderEquity, last quarter 21.79b)
Debt / EBITDA = 2.86 (Net Debt 13.34b / EBITDA 4.66b)
Debt / FCF = 3.27 (Net Debt 13.34b / FCF TTM 4.07b)
Total Stockholder Equity = 21.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.25% (Net Income 2.94b / Total Assets 47.06b)
RoE = 13.92% (Net Income TTM 2.94b / Total Stockholder Equity 21.14b)
RoCE = 9.72% (EBIT 3.50b / Capital Employed (Equity 21.14b + L.T.Debt 14.85b))
RoIC = 7.88% (NOPAT 2.92b / Invested Capital 37.02b)
WACC = 7.77% (E(142.37b)/V(158.97b) * Re(8.58%) + D(16.59b)/V(158.97b) * Rd(0.96%) * (1-Tc(0.17)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF Debug] Terminal Value 79.72% ; FCFE base≈3.73b ; Y1≈4.60b ; Y5≈7.84b
Fair Price DCF = 314.5 (DCF Value 120.26b / Shares Outstanding 382.4m; 5y FCF grow 24.98% → 3.0% )
EPS Correlation: 38.79 | EPS CAGR: 4.44% | SUE: 0.24 | # QB: 0
Revenue Correlation: 90.00 | Revenue CAGR: 6.99% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.06 | Chg30d=-0.001 | Revisions Net=+3 | Analysts=20
EPS next Year (2026-12-31): EPS=14.94 | Chg30d=+0.009 | Revisions Net=+5 | Growth EPS=+10.3% | Growth Revenue=+8.6%
P/E Trailing = 49.0501
P/E Forward = 24.8756
P/S = 5.8395
P/B = 6.5353
P/EG = 1.8997
Beta = 0.899
Revenue TTM = 24.38b USD
EBIT TTM = 3.50b USD
EBITDA TTM = 4.66b USD
Long Term Debt = 14.85b USD (from longTermDebt, last quarter)
Short Term Debt = 1.75b USD (from shortTermDebt, last quarter)
Debt = 16.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.34b USD (from netDebt column, last quarter)
Enterprise Value = 155.62b USD (142.37b + Debt 16.59b - CCE 3.34b)
Interest Coverage Ratio = 21.99 (Ebit TTM 3.50b / Interest Expense TTM 159.0m)
FCF Yield = 2.62% (FCF TTM 4.07b / Enterprise Value 155.62b)
FCF Margin = 16.71% (FCF TTM 4.07b / Revenue TTM 24.38b)
Net Margin = 12.07% (Net Income TTM 2.94b / Revenue TTM 24.38b)
Gross Margin = 62.63% ((Revenue TTM 24.38b - Cost of Revenue TTM 9.11b) / Revenue TTM)
Gross Margin QoQ = 63.60% (prev 62.27%)
Tobins Q-Ratio = 3.31 (Enterprise Value 155.62b / Total Assets 47.06b)
Interest Expense / Debt = 0.96% (Interest Expense 159.0m / Debt 16.59b)
Taxrate = 16.52% (170.0m / 1.03b)
NOPAT = 2.92b (EBIT 3.50b * (1 - 16.52%))
Current Ratio = 1.85 (Total Current Assets 13.71b / Total Current Liabilities 7.41b)
Debt / Equity = 0.76 (Debt 16.59b / totalStockholderEquity, last quarter 21.79b)
Debt / EBITDA = 2.86 (Net Debt 13.34b / EBITDA 4.66b)
Debt / FCF = 3.27 (Net Debt 13.34b / FCF TTM 4.07b)
Total Stockholder Equity = 21.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.25% (Net Income 2.94b / Total Assets 47.06b)
RoE = 13.92% (Net Income TTM 2.94b / Total Stockholder Equity 21.14b)
RoCE = 9.72% (EBIT 3.50b / Capital Employed (Equity 21.14b + L.T.Debt 14.85b))
RoIC = 7.88% (NOPAT 2.92b / Invested Capital 37.02b)
WACC = 7.77% (E(142.37b)/V(158.97b) * Re(8.58%) + D(16.59b)/V(158.97b) * Rd(0.96%) * (1-Tc(0.17)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.36%
[DCF Debug] Terminal Value 79.72% ; FCFE base≈3.73b ; Y1≈4.60b ; Y5≈7.84b
Fair Price DCF = 314.5 (DCF Value 120.26b / Shares Outstanding 382.4m; 5y FCF grow 24.98% → 3.0% )
EPS Correlation: 38.79 | EPS CAGR: 4.44% | SUE: 0.24 | # QB: 0
Revenue Correlation: 90.00 | Revenue CAGR: 6.99% | SUE: 0.18 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.06 | Chg30d=-0.001 | Revisions Net=+3 | Analysts=20
EPS next Year (2026-12-31): EPS=14.94 | Chg30d=+0.009 | Revisions Net=+5 | Growth EPS=+10.3% | Growth Revenue=+8.6%
Additional Sources for SYK Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle